ArticleAmerican journal of cancer research2026
Relationship between morphine rescue dose and respiratory safety during breakthrough cancer pain in lung cancer patients treated with high-dose opioids.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the efficacy and safety of different morphine rescue doses for breakthrough cancer pain (BTcP) in lung cancer patients receiving high-dose opioid therapy. Between August 2023 and January 2025, 150 hospitalized patients with at least one documented BTcP episode were retrospectively assigned to three groups based on their initial rescue dose: a fixed 10 mg dose (Group A, n=47), 5% of their daily opioid dose (Group B, n=62), and 10% of their daily opioid dose (Group C, n=41). Pain intensity (numerical rating scale, NRS) and vital signs were recorded at baseline and up to 180 minutes after administration. The primary outcome was the proportion of patients with a ≥30% or ≥50% reduction in NRS at 60 minutes; safety outcomes included a ≥5% reduction in respiratory rate or oxygen saturation (SpO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.